Infertility is a growing problem that affects millions of people worldwide. Medical procedures known as in vitro fertilization (IVF) help many individuals experiencing infertility to have children. Typically in IVF, a woman’s egg cells are collected, fertilized with sperm from a chosen male and grown for a few days in a laboratory, before returning them to the woman’s body to continue to develop.

However, there are some women whose egg cells cannot develop into a healthy baby after they have been fertilized. Many of these patients use egg cells from donors, instead. This greatly improves the chances of the IVF treatment being successful, but the resultant children are not genetically related to the intended mothers.

Previous studies suggested that a cell compartment known as the cytoplasm plays a crucial role in allowing fertilized egg cells to develop normally. A new technique known as maternal spindle transfer, often shortened to MST, makes it possible to replace the entire cytoplasm of a compromised egg cell. This is achieved by transplanting the genetic material of the compromised egg cell into a donor egg cell with healthier cytoplasm that has previously had its own genetic material removed. Using this technique, it is possible to generate human egg cells for IVF that have the genetic material from the intended mother without the defects in the cytoplasm that may be responsible for infertility. However, it is not clear whether this approach would be a safe and effective way to treat infertility in humans.

Costa-Borges et al. applied MST to infertile female mice and found that the technique could permanently correct deficiencies in the cytoplasms of poor quality egg cells, allowing the mice to give birth to healthy offspring. Further experiments studied the offspring and their descendants over several generations and found that they also had higher quality egg cells and normal levels of fertility.

These findings open up the possibility of developing new treatments for infertility caused by problems with egg cells, so experiments involving human egg cells are now being performed to evaluate the safety and effectiveness of the technique.

Infertility disorders are a growing problem that affects millions of couples worldwide (WHO, 2017). Although assisted reproductive technologies (ARTs) have evolved and can now successfully address many challenging cases (Huang and Rosenwaks, 2014; Niederberger et al., 2018), conventional IVF treatment continues to fail a significant percentage of infertile women, with many ultimately ending-up being enrolled in egg donation programs (Lutjen et al., 1984; Sauer et al., 1990; Trounson et al., 1983). The use of donated oocytes is effective at significantly improving the chances of successful IVF treatment, however, the resultant children are not genetically related to the intended-mothers. Therefore, it is desirable to develop new reproductive strategies that can allow the treatment of these patients with genetically related oocytes.

Oocyte quality is defined as the competence of the oocyte to develop into a chromosomally normal blastocyst with potential to sustain a pregnancy up to a healthy live birth. Frequently, poor quality oocytes fail to fertilize or produce embryos that arrest during the first stages of development (Hardy et al., 2001; Meskhi and Seif, 2006; Pellicer et al., 1995) either due to nuclear or cytoplasmic defects (Conti and Franciosi, 2018; Eppig, 1996; Liu and Keefe, 2004). Accumulated evidence suggests that aberrant meiosis or early developmental failure is caused mainly by deficiencies in the oocyte cytoplasmic machinery (Hoffmann et al., 2012; Liu et al., 2003; Liu et al., 1999; Liu et al., 2000; Liu and Keefe, 2007; Reader et al., 2017), which contains a vast diversity of critical components, including organelles, mRNAs, proteins, ribosomes and many other factors (Bianchi et al., 2015; Sathananthan, 1997). Mitochondria are the most numerous organelles in the cytoplasm and play an essential role by supplying the ATP needed for the oocyte to support critical events, such as: maturation, spindle formation and segregation of chromosomes and chromatids (Chappel, 2013; May-Panloup et al., 2007). Dysfunctions at the mitochondrial level and deficiencies affecting other cytoplasmic factors have been correlated with inadequate oocyte developmental competence (Eichenlaub-Ritter, 2012; Liu et al., 2002; Van Blerkom, 2011; Van Blerkom et al., 1995), particularly in older infertile patients (Babayev and Seli, 2015; Fragouli et al., 2015; Igarashi et al., 2016; Wells, 2017).

Techniques like cytoplasmic transfer (Cohen et al., 1998; Lanzendorf et al., 1999) or the injection of purified mitochondria (Fakih MHSM et al., 2015; Kristensen et al., 2017 have been proposed as potential methods to restore the viability of compromised oocytes in IVF patients with a history of poor embryo development or repeated implantation failures with conventional treatments. Although live births have been reported following the use of these techniques (Cohen et al., 1998; Fakih MHSM et al., 2015; Huang et al., 1999; Lanzendorf et al., 1999) their safety and/or benefits to treat infertility has been questioned. Cytoplasmic transfer experiments were abandoned due to concerns that heteroplasmy (i.e., the co-existence of two distinct mtDNA genomes) might have negative clinical consequences (Darbandi et al., 2017; Isasi et al., 2016; Kristensen et al., 2017). An alternative strategy, which avoided heteroplasmy by utilizing autologous injection of mitochondria from the patient's own germline cells attracted much attention as a possible new treatment to revitalize deficient oocytes (Johnson et al., 2004; White et al., 2012). Multiple studies in animal models showed apparent benefits of the addition of mitochondria to oocytes of compromised quality (El Shourbagy et al., 2006; Hua et al., 2007; Yi et al., 2007) and IVF births were reported after transfer of oogonial precursor cell-derived mitochondria (Fakih MHSM et al., 2015). However, the source and quality of the mitochondria used are unclear and a recent randomized clinical study conducted using mitochondria derived from autologous oogonial stem cells failed to demonstrate improvements in embryo developmental or clinical outcomes (Labarta et al., 2019). Thus, current data from human clinical research do not support the notion that the addition of further mitochondria derived from the same individual is capable of correcting cytoplasmic deficiencies (mitochondria or other) that may be present in poor quality oocytes. Furthermore, the safety of the procedure is yet to be verified. Of note, a recent study suggested that autologous mitochondrial supplementation may induce a phenotypic effect in the heart of resultant mice (St John et al., 2019).

An approach that may offer greater promise in terms of its capacity to address infertility problems of maternal (oocyte) origin is the transfer of the nuclear genome from an affected oocyte or zygote into a new ‘healthy’ cytoplasm. These techniques, known globally as mitochondrial replacement techniques (MRTs) were originally proposed to prevent the transmission of inherited mitochondrial diseases (Craven et al., 2010; Hyslop et al., 2016; Paull et al., 2013; Tachibana et al., 2009). Indeed, a clinical application of maternal spindle transfer (MST) to prevent the transmission of Leigh Syndrome was recently reported, resulting the birth of an unaffected child (Zhang et al., 2017). However, the potential of MRTs to overcome infertility remains unclear, as most studies utilizing this approach have not had this as their main focus, instead concentrating on their potential to avoid mitochondrial diseases; examination of nuclear-cytoplasmic interactions in oocytes and zygotes (Liu and Keefe, 2004; Liu and Keefe, 2007); the origin of female aneuploidies Palermo et al., 2002; or the decreased developmental capability of aged oocytes in animal models (Yamada and Egli, 2017).

Here, we explored the feasibility of the MST technique as a reproductive tool to overcome embryo developmental arrest. To test our hypothesis, a detailed series of proof-of-concept experiments were conducted to assess the safety and the efficiency of the technique using mouse models, which, in a clinical context, could represent donors and patients with oocytes of good and poor developmental competence, respectively. Additionally, advanced molecular techniques were used to evaluate in detail the heteroplasmy levels induced by the procedure in early embryonic-stages and in multiple important organs, including some with high metabolic demand, collected from male and female mice generated by MST. The mice were bred and followed up to ascertain their health, fertility and welfare, as well as, to study the fate of the heteroplasmy in the offspring of the MST female progenitors over five generations.

MST is a technique that was originally proposed to prevent the transmission of mitochondrial diseases. This proof of concept study provides insights into the feasibility of this technique as a potential new reproductive approach to overcome infertility problems characterized by repeated in vitro embryo development arrest caused by cytoplasmic deficiencies in the oocyte.

Herein, it is shown that MST can be carried out with high efficiency in the mouse, with successful enucleation and reconstruction achieved for >95% of oocytes. Furthermore, the data produced indicate that, as long as all the steps of the protocol are well optimized and care is taken to minimize the risk of damage to the oocyte, the procedure does not negatively affect the spindle apparatus or early embryo development. In the event of a future clinical application of MST in humans, it may be difficult to coordinate the retrieval of mature oocytes from patients and donors, due to the inherent variation in ovarian responses to hormonal stimulation. For this reason, the capacity of cryopreserved oocytes to substitute for fresh oocytes, when serving as spindle or cytoplast donors, was evaluated. The results indicated that fresh and vitrified oocytes are equally suitable for use as spindle donors, but superior results are obtained if the recipient cytoplast is fresh. This agrees with a previous report performed in non-human primates that had shown that fresh spindles transplanted into vitrified cytoplasts results in impaired (50%) fertilization after ICSI, while the reciprocal spindle transfer resulted in fertilization (88%) and blastocyst formation (68%) rates similar to fresh controls (Tachibana et al., 2009). This also represents an advantage in the clinical setting, where low-responders to ovarian stimulation could vitrify oocytes from repeated oocyte collections, and the accumulated oocytes be used for MST using freshly collected donor cytoplasts.

Additionally, MST was conducted between two distantly related mouse strains with the aim of simulating a clinical context, in which donors with oocytes of good reproductive competence provide cytoplasts for patients with a history of poor oocyte fertilization and/or high rates of failed embryo development. The experiments demonstrated how the successful replacement of the entire cytoplasm of compromised oocytes has the potential to overcome the massive embryo development arrest phenotype, which is observed in non-manipulated controls from a sensitive mouse strain (NZB). This strategy resulted in a highly significant (10-fold) increase in blastocyst formation rates, as well as an increased likelihood of embryo development to term, compared to non-manipulated control oocytes. These results highlight the importance of the cytoplasm on the potential of the oocyte to support embryo development in vitro and to lay the foundations for a successful pregnancy. Consistent with this data, Mitsui and colleagues showed that oocyte genomes from mice aged 10–12 months transferred into oocytes of young mice aged 3–5 months, resulted in increased term-development from 6.3% for in vivo aged oocytes to 27.1% for the reconstructed oocytes (Mitsui et al., 2009). Similarly, a recent study demonstrated that in vitro aged oocytes accumulate cytoplasmic deficiencies if they are maintained in culture for an extended period prior to fertilization, and that these deficiencies can be overcome with spindle transfer (Yamada and Egli, 2017). However, in both cases, studies were performed between oocytes from the same mouse strain and thus the potential of the technique to overcome infertility in a strain with poor fertility competence remained undetermined. It is noteworthy that the current study employed ICSI to inseminate oocytes, rather than conventional IVF, which resembles closely the standard protocol used in humans for oocytes that have been denuded of the surrounding cumulus cells.

Levels of mtDNA heteroplasmy caused by carryover of mitochondria in close proximity to spindle during the MST procedure were also evaluated. Clearly, this is an important consideration when utilizing MST technology to avoid transmission of mtDNA mutations responsible for serious inherited disorders, but it is also relevant to other variations in the mtDNA, or other defects affecting the mitochondrial organelle, which may potentially contribute to certain forms of embryonic developmental arrest. As well as assessing the extent of heteroplasmy at different embryonic stages, the levels were also assessed in multiple tissues in adulthood and over several generations. There are conflicting reports regarding the dynamics of mtDNA heteroplasmy during the lifetime of an individual, between organs or even during in vitro culture when ESCs have been derived from MRT embryos with heteroplasmic mtDNA (Hyslop et al., 2016; Kang et al., 2016; Paull et al., 2013). It is also unclear to what extent divergent mtDNA haplotypes in heteroplasmic organisms might lead to functional incompatibility, either between the two types of mitochondria or between the mitochondrial and nuclear genomes.

This study confirms that cells biopsied from MST embryos at the morula or blastocyst stages present minimal levels of heteroplasmy (<2.9% mtDNA from the spindle donor) and that these biopsy specimens are representative of the remainder of the embryo. On the contrary, the heteroplasmy levels were significantly higher in second polar bodies than in blastomere or trophectoderm biopsies. This agrees with data from Neupane and colleagues, who have shown that, in comparison to second polar bodies, mtDNA heteroplasmy in TE cells is more closely correlated with the levels in the blastocyst as a whole or the corresponding ESCs (Neupane et al., 2014). Alternatively, oocytes might be actively removing mitochondria transferred along with the spindle, since they may be disadvantageous as compared to the recipient’s own organelles (De Fanti et al., 2017). However, perhaps the most likely explanation is that when the meiotic spindle is transferred, a number of mitochondria accompany it. These mitochondria are likely to remain in the vicinity of the MII spindle and consequently it is inevitable that a disproportionate number of these mitochondria will pass into the second polar body. Regardless of the underlying mechanism, our data suggest that testing of blastomeres or TE biopsies is preferable to second polar body analysis for the quantification of mtDNA heteroplasmy levels. This also has relevance for the preimplantation genetic testing (PGT, also known as preimplantation genetic diagnosis – PGD) of mitochondrial disease in the human.

The data from our current study revealed that mtDNA heteroplasmy levels were low in all the adult mice produced, regardless of gender, or the type of organ (range 0–6%). Previous studies in monkeys and humans have shown that a minimal number of donor mitochondria are transferred using MRT (below 1–2%) (Craven et al., 2010; Hyslop et al., 2016; Paull et al., 2013; Tachibana et al., 2009). Nevertheless, since the meiotic spindle in mouse oocytes is much larger than that of the human, and given that multiple mitochondria are found in the vicinity of the spindle, it was expected that MST in mice would lead to higher mtDNA carryover levels. The surprisingly low heteroplasmic levels achieved during this study can likely be attributed to the use of birefringence microscopy during enucleation, which assists in minimizing the carryover of cytoplasm transferred along the meiotic spindle.

It has also been suggested that organs with a high-metabolic demand tend to accumulate higher heteroplasmy mtDNA levels (Jenuth et al., 1997; Meirelles and Smith, 1997), however, our data do not confirm this observation. This result could be explained by differences in mitochondrial haplotypes from mouse strains used, which could have a differential replication rate.

Some studies of heteroplasmic ESC lines derived from embryos carrying mtDNA mutations have shown changes in the levels of normal and mutant mtDNA during prolonged in vitro culture, with reversion back to a situation where mutant mtDNA predominates (Hyslop et al., 2016; Kang et al., 2016; Paull et al., 2013). This delayed efforts for the direct application of MRT-derived techniques in the clinical setting and raises some concerns for the first baby born using MST (Zhang et al., 2017). Nevertheless, the results presented here show a low level of mtDNA carryover in all adult organs analyzed, suggesting that the mechanism seen in ESCs in vitro might not necessarily represent the in vivo process. The results also agree with Sharpley et al, who showed that NZB and 129S6 mtDNA heteroplasmic haplotypes decrease over generations (Sharpley et al., 2012). In the current study, heteroplasmy was very low in the F2 progeny and undetected in the offspring of the subsequent generations (up to F5). The data collected from the analyzed organs suggests that heteroplasmy resultant from MST can be stable within an individual and can lead to an homoplasmic state within a few generations. However, additional work should be done in order to comprehensively assess how mtDNA heteroplasmy segregates in other organs.

On the other hand, the MST mice followed over five generations were apparently normal and showed good fertility (average of 7.8 pups per litter). This is a notable observation, as based on the literature, NZB/OlaHsd mice are expected to have small litter sizes (3.8 at weaning) (Fernandes et al., 1973; Hansen CT and Whitney, 1973). Additionally, histological examinations in F1 MST mice did not reveal any lesions in a selection of organs. Whether the MST technique can potentially reveal mitochondrial causes of infertility that are hereditary or aggravated with lifestyle or age is a question that remains to be answered and will require additional studies.

In conclusion, this study has demonstrated that MST can overcome a severe developmental arrest phenotype, associated with poor fertility and greatly reduced chances of an individual oocyte producing a pregnancy following in vitro fertilization. The results show that embryos produced using optimized MST techniques can give rise to apparently normal and fertile animals. Levels of heteroplasmy were low in the initial generation and undetectable in subsequent generations, indicating that homoplasmy for the mtDNA of the cytoplast donor is rapidly attained in this model. Given the high proportion of IVF cycles which are unsuccessful due to poor embryo development related to low oocyte quality, we believe that there is a need to further explore the potential of MST as a clinical treatment for infertility. Pre-clinical and clinical trials involving human oocytes, undertaken in a regulated and carefully controlled manner, is desirable, since such a therapy could represent the last chance for infertile patients to have genetically related children.

All data generated or analysed during this study are included in the manuscript and supporting files.

1. 1. Babayev E
   2. Seli E

   (2015) Oocyte mitochondrial function and reproduction

   Current Opinion in Obstetrics and Gynecology 27:175–181.

   https://doi.org/10.1097/GCO.0000000000000164

   • PubMed
   • Google Scholar
2. 1. Bianchi S
   2. Macchiarelli G
   3. Micara G
   4. Linari A
   5. Boninsegna C
   6. Aragona C
   7. Rossi G
   8. Cecconi S
   9. Nottola SA

   (2015) Ultrastructural markers of quality are impaired in human metaphase II aged oocytes: a comparison between reproductive and in vitro aging

   Journal of Assisted Reproduction and Genetics 32:1343–1358.

   https://doi.org/10.1007/s10815-015-0552-9

   • PubMed
   • Google Scholar
3. 1. Bielschowsky M
   2. Goodall CM

   (1970)

   Origin of inbred NZ mouse strains

   Cancer Research 30:834–836.

   • PubMed
   • Google Scholar
4. 1. Chappel S

   (2013) The role of mitochondria from mature oocyte to viable blastocyst

   Obstetrics and Gynecology International 2013:1–10.

   https://doi.org/10.1155/2013/183024

   • Google Scholar
5. 1. Cohen J
   2. Scott R
   3. Alikani M
   4. Schimmel T
   5. Munné S
   6. Levron J
   7. Wu L
   8. Brenner C
   9. Warner C
   10. Willadsen S

   (1998) Ooplasmic transfer in mature human oocytes

   Molecular Human Reproduction 4:269–280.

   https://doi.org/10.1093/molehr/4.3.269

   • PubMed
   • Google Scholar
6. 1. Conti M
   2. Franciosi F

   (2018) Acquisition of oocyte competence to develop as an embryo: integrated nuclear and cytoplasmic events

   Human Reproduction Update 24:245–266.

   https://doi.org/10.1093/humupd/dmx040

   • PubMed
   • Google Scholar
7. 1. Costa-Borges N
   2. Santaló J
   3. Ibáñez E

   (2010) Comparison between the effects of valproic acid and trichostatin A on the in vitro development, blastocyst quality, and full-term development of mouse somatic cell nuclear transfer embryos

   Cellular Reprogramming 12:437–446.

   https://doi.org/10.1089/cell.2009.0108

   • PubMed
   • Google Scholar
8. 1. Craven L
   2. Tuppen HA
   3. Greggains GD
   4. Harbottle SJ
   5. Murphy JL
   6. Cree LM
   7. Murdoch AP
   8. Chinnery PF
   9. Taylor RW
   10. Lightowlers RN
   11. Herbert M
   12. Turnbull DM

   (2010) Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease

   Nature 465:82–85.

   https://doi.org/10.1038/nature08958

   • PubMed
   • Google Scholar
9. 1. Darbandi S
   2. Darbandi M
   3. Khorram Khorshid HR
   4. Sadeghi MR
   5. Agarwal A
   6. Sengupta P
   7. Al-Hasani S
   8. Akhondi MM

   (2017) Ooplasmic transfer in human oocytes: efficacy and concerns in assisted reproduction

   Reproductive Biology and Endocrinology 15:77.

   https://doi.org/10.1186/s12958-017-0292-z

   • PubMed
   • Google Scholar
10. 1. De Fanti S
    2. Vicario S
    3. Lang M
    4. Simone D
    5. Magli C
    6. Luiselli D
    7. Gianaroli L
    8. Romeo G

    (2017) Intra-individual purifying selection on mitochondrial DNA variants during human oogenesis

    Human Reproduction 32:1100–1107.

    https://doi.org/10.1093/humrep/dex051

    • PubMed
    • Google Scholar
11. 1. Eichenlaub-Ritter U

    (2012) Female meiosis and beyond: more questions than answers?

    Reproductive BioMedicine Online 24:589–590.

    https://doi.org/10.1016/j.rbmo.2012.04.007

    • PubMed
    • Google Scholar
12. 1. El Shourbagy SH
    2. Spikings EC
    3. Freitas M
    4. St John JC

    (2006) Mitochondria directly influence fertilisation outcome in the pig

    Reproduction 131:233–245.

    https://doi.org/10.1530/rep.1.00551

    • PubMed
    • Google Scholar
13. 1. Eppig JJ

    (1996) Coordination of nuclear and cytoplasmic oocyte maturation in eutherian mammals

    Reproduction, Fertility and Development 8:485–489.

    https://doi.org/10.1071/RD9960485

    • PubMed
    • Google Scholar
14. 1. Fakih MHSM SJ
    2. dela Cruz DB
    3. Lux C
    4. Verjee S
    5. Burgess CM
    6. Cohn GM
    7. Casper RF

    (2015) The AUGMENT treatment: physician reported outcomes of the initial global patient experience

    JFIV Reprod Med Genet 3:154.

    https://doi.org/10.4172/2375-4508.1000154

    • Google Scholar
15. 1. Fernandes G
    2. Yunis EJ
    3. Good RA

    (1973)

    Reproductive deficiency of NZB male mice. Possibility of a viral basis

    Laboratory Investigation; a Journal of Technical Methods and Pathology 29:278–281.

    • PubMed
    • Google Scholar
16. 1. Fragouli E
    2. Spath K
    3. Alfarawati S
    4. Kaper F
    5. Craig A
    6. Michel CE
    7. Kokocinski F
    8. Cohen J
    9. Munne S
    10. Wells D

    (2015) Altered levels of mitochondrial DNA are associated with female age, Aneuploidy, and provide an independent measure of embryonic implantation potential

    PLOS Genetics 11:e1005241.

    https://doi.org/10.1371/journal.pgen.1005241

    • PubMed
    • Google Scholar
17. Book

    1. Hansen CT JF
    2. Whitney RA

    (1973)

    Catalog of NIH Rodents

    DHEW Publication (NIH).

    • Google Scholar
18. 1. Hardy K
    2. Spanos S
    3. Becker D
    4. Iannelli P
    5. Winston RM
    6. Stark J

    (2001) From cell death to embryo arrest: mathematical models of human preimplantation embryo development

    PNAS 98:1655–1660.

    https://doi.org/10.1073/pnas.98.4.1655

    • PubMed
    • Google Scholar
19. 1. Hoffmann S
    2. Król M
    3. Polanski Z

    (2012) Spindle assembly checkpoint-related meiotic defect in oocytes from LT/Sv mice has cytoplasmic origin and diminishes in older females

    Reproduction 144:331–338.

    https://doi.org/10.1530/REP-11-0362

    • PubMed
    • Google Scholar
20. 1. Hua S
    2. Zhang Y
    3. Li XC
    4. Ma LB
    5. Cao JW
    6. Dai JP
    7. Li R

    (2007) Effects of granulosa cell mitochondria transfer on the early development of bovine embryos in vitro

    Cloning and Stem Cells 9:237–246.

    https://doi.org/10.1089/clo.2006.0020

    • PubMed
    • Google Scholar
21. 1. Huang CC
    2. Cheng TC
    3. Chang HH
    4. Chang CC
    5. Chen CI
    6. Liu J
    7. Lee MS

    (1999) Birth after the injection of sperm and the cytoplasm of tripronucleate zygotes into metaphase II oocytes in patients with repeated implantation failure after assisted fertilization procedures

    Fertility and Sterility 72:702–706.

    https://doi.org/10.1016/S0015-0282(99)00309-X

    • PubMed
    • Google Scholar
22. 1. Huang JY
    2. Rosenwaks Z

    (2014) Assisted reproductive techniques

    Methods in Molecular Biology 1154:171–231.

    https://doi.org/10.1007/978-1-4939-0659-8_8

    • PubMed
    • Google Scholar
23. 1. Hyslop LA
    2. Blakeley P
    3. Craven L
    4. Richardson J
    5. Fogarty NM
    6. Fragouli E
    7. Lamb M
    8. Wamaitha SE
    9. Prathalingam N
    10. Zhang Q
    11. O'Keefe H
    12. Takeda Y
    13. Arizzi L
    14. Alfarawati S
    15. Tuppen HA
    16. Irving L
    17. Kalleas D
    18. Choudhary M
    19. Wells D
    20. Murdoch AP
    21. Turnbull DM
    22. Niakan KK
    23. Herbert M

    (2016) Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease

    Nature 534:383–386.

    https://doi.org/10.1038/nature18303

    • PubMed
    • Google Scholar
24. 1. Igarashi H
    2. Takahashi T
    3. Abe H
    4. Nakano H
    5. Nakajima O
    6. Nagase S

    (2016) Poor embryo development in post-ovulatory in vivo-aged mouse oocytes is associated with mitochondrial dysfunction, but mitochondrial transfer from somatic cells is not sufficient for rejuvenation

    Human Reproduction 31:2331–2338.

    https://doi.org/10.1093/humrep/dew203

    • PubMed
    • Google Scholar
25. 1. Isasi R
    2. Kleiderman E
    3. Knoppers BM

    (2016) Editing policy to fit the genome?

    Science 351:337–339.

    https://doi.org/10.1126/science.aad6778

    • Google Scholar
26. 1. Jenuth JP
    2. Peterson AC
    3. Shoubridge EA

    (1997) Tissue-specific selection for different mtDNA genotypes in heteroplasmic mice

    Nature Genetics 16:93–95.

    https://doi.org/10.1038/ng0597-93

    • PubMed
    • Google Scholar
27. 1. Johnson J
    2. Canning J
    3. Kaneko T
    4. Pru JK
    5. Tilly JL

    (2004) Germline stem cells and follicular renewal in the postnatal mammalian ovary

    Nature 428:145–150.

    https://doi.org/10.1038/nature02316

    • Google Scholar
28. 1. Kang E
    2. Wu J
    3. Gutierrez NM
    4. Koski A
    5. Tippner-Hedges R
    6. Agaronyan K
    7. Platero-Luengo A
    8. Martinez-Redondo P
    9. Ma H
    10. Lee Y
    11. Hayama T
    12. Van Dyken C
    13. Wang X
    14. Luo S
    15. Ahmed R
    16. Li Y
    17. Ji D
    18. Kayali R
    19. Cinnioglu C
    20. Olson S
    21. Jensen J
    22. Battaglia D
    23. Lee D
    24. Wu D
    25. Huang T
    26. Wolf DP
    27. Temiakov D
    28. Belmonte JC
    29. Amato P
    30. Mitalipov S

    (2016) Mitochondrial replacement in human oocytes carrying pathogenic mitochondrial DNA mutations

    Nature 540:270–275.

    https://doi.org/10.1038/nature20592

    • PubMed
    • Google Scholar
29. 1. Kristensen SG
    2. Pors SE
    3. Andersen CY

    (2017) Improving oocyte quality by transfer of autologous mitochondria from fully grown oocytes

    Human Reproduction 32:1–8.

    https://doi.org/10.1093/humrep/dex043

    • PubMed
    • Google Scholar
30. 1. Labarta E
    2. de Los Santos MJ
    3. Herraiz S
    4. Escribá MJ
    5. Marzal A
    6. Buigues A
    7. Pellicer A

    (2019) Autologous mitochondrial transfer as a complementary technique to intracytoplasmic sperm injection to improve embryo quality in patients undergoing in vitro fertilization-a randomized pilot study

    Fertility and Sterility 111:86–96.

    https://doi.org/10.1016/j.fertnstert.2018.09.023

    • PubMed
    • Google Scholar
31. 1. Lanzendorf SE
    2. Mayer JF
    3. Toner J
    4. Oehninger S
    5. Saffan DS
    6. Muasher S

    (1999) Pregnancy following transfer of ooplasm from cryopreserved-thawed donor oocytes into recipient oocytes

    Fertility and Sterility 71:575–577.

    https://doi.org/10.1016/S0015-0282(98)00504-4

    • PubMed
    • Google Scholar
32. 1. Liu H
    2. Wang CW
    3. Grifo JA
    4. Krey LC
    5. Zhang J

    (1999) Reconstruction of mouse oocytes by germinal vesicle transfer: maturity of host oocyte cytoplasm determines meiosis

    Human Reproduction 14:2357–2361.

    https://doi.org/10.1093/humrep/14.9.2357

    • PubMed
    • Google Scholar
33. 1. Liu H
    2. Zhang J
    3. Krey LC
    4. Grifo JA

    (2000) In-vitro development of mouse zygotes following reconstruction by sequential transfer of germinal vesicles and haploid pronuclei

    Human Reproduction 15:1997–2002.

    https://doi.org/10.1093/humrep/15.9.1997

    • PubMed
    • Google Scholar
34. 1. Liu L
    2. Trimarchi JR
    3. Smith PJ
    4. Keefe DL

    (2002) Mitochondrial dysfunction leads to telomere attrition and genomic instability

    Aging Cell 1:40–46.

    https://doi.org/10.1046/j.1474-9728.2002.00004.x

    • PubMed
    • Google Scholar
35. 1. Liu H
    2. Chang HC
    3. Zhang J
    4. Grifo J
    5. Krey LC

    (2003) Metaphase II nuclei generated by germinal vesicle transfer in mouse oocytes support embryonic development to term

    Human Reproduction 18:1903–1907.

    https://doi.org/10.1093/humrep/deg372

    • PubMed
    • Google Scholar
36. 1. Liu L
    2. Keefe DL

    (2004) Nuclear origin of aging-associated meiotic defects in senescence-accelerated mice

    Biology of Reproduction 71:1724–1729.

    https://doi.org/10.1095/biolreprod.104.028985

    • PubMed
    • Google Scholar
37. 1. Liu L
    2. Keefe DL

    (2007) Nuclear transfer methods to study aging

    Methods in Molecular Biology 371:191–207.

    https://doi.org/10.1007/978-1-59745-361-5_15

    • PubMed
    • Google Scholar
38. 1. Lutjen P
    2. Trounson A
    3. Leeton J
    4. Findlay J
    5. Wood C
    6. Renou P

    (1984) The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure

    Nature 307:174–175.

    https://doi.org/10.1038/307174a0

    • PubMed
    • Google Scholar
39. 1. May-Panloup P
    2. Chretien MF
    3. Malthiery Y
    4. Reynier P

    (2007) Mitochondrial DNA in the oocyte and the developing embryo

    Current Topics in Developmental Biology 77:51–83.

    https://doi.org/10.1016/S0070-2153(06)77003-X

    • PubMed
    • Google Scholar
40. 1. Meirelles FV
    2. Smith LC

    (1997)

    Mitochondrial genotype segregation in a mouse heteroplasmic lineage produced by embryonic karyoplast transplantation

    Genetics 145:445–451.

    • PubMed
    • Google Scholar
41. 1. Meskhi A
    2. Seif MW

    (2006) Premature ovarian failure

    Current Opinion in Obstetrics and Gynecology 18:418–426.

    https://doi.org/10.1097/01.gco.0000233937.36554.d3

    • PubMed
    • Google Scholar
42. 1. Messinger SM
    2. Albertini DF

    (1991)

    Centrosome and microtubule dynamics during meiotic progression in the mouse oocyte

    Journal of Cell Science 100 ( Pt 2:289–298.

    • PubMed
    • Google Scholar
43. 1. Mitsui A
    2. Yoshizawa M
    3. Matsumoto H
    4. Fukui E

    (2009) Improvement of embryonic development and production of offspring by transferring meiosis-II chromosomes of senescent mouse oocytes into cytoplasts of young mouse oocytes

    Journal of Assisted Reproduction and Genetics 26:35–39.

    https://doi.org/10.1007/s10815-008-9282-6

    • PubMed
    • Google Scholar
44. 1. Neupane J
    2. Vandewoestyne M
    3. Heindryckx B
    4. Ghimire S
    5. Lu Y
    6. Qian C
    7. Lierman S
    8. Van Coster R
    9. Gerris J
    10. Deroo T
    11. Deforce D
    12. De Sutter P

    (2014) A systematic analysis of the suitability of preimplantation genetic diagnosis for mitochondrial diseases in a heteroplasmic mitochondrial mouse model

    Human Reproduction 29:852–859.

    https://doi.org/10.1093/humrep/deu016

    • PubMed
    • Google Scholar
45. 1. Niederberger C
    2. Pellicer A
    3. Cohen J
    4. Gardner DK
    5. Palermo GD
    6. O'Neill CL
    7. Chow S
    8. Rosenwaks Z
    9. Cobo A
    10. Swain JE
    11. Schoolcraft WB
    12. Frydman R
    13. Bishop LA
    14. Aharon D
    15. Gordon C
    16. New E
    17. Decherney A
    18. Tan SL
    19. Paulson RJ
    20. Goldfarb JM
    21. Brännström M
    22. Donnez J
    23. Silber S
    24. Dolmans MM
    25. Simpson JL
    26. Handyside AH
    27. Munné S
    28. Eguizabal C
    29. Montserrat N
    30. Izpisua Belmonte JC
    31. Trounson A
    32. Simon C
    33. Tulandi T
    34. Giudice LC
    35. Norman RJ
    36. Hsueh AJ
    37. Sun Y
    38. Laufer N
    39. Kochman R
    40. Eldar-Geva T
    41. Lunenfeld B
    42. Ezcurra D
    43. D'Hooghe T
    44. Fauser B
    45. Tarlatzis BC
    46. Meldrum DR
    47. Casper RF
    48. Fatemi HM
    49. Devroey P
    50. Galliano D
    51. Wikland M
    52. Sigman M
    53. Schoor RA
    54. Goldstein M
    55. Lipshultz LI
    56. Schlegel PN
    57. Hussein A
    58. Oates RD
    59. Brannigan RE
    60. Ross HE
    61. Pennings G
    62. Klock SC
    63. Brown S
    64. Van Steirteghem A
    65. Rebar RW
    66. LaBarbera AR

    (2018) Forty years of IVF

    Fertility and Sterility 110:185–324.

    https://doi.org/10.1016/j.fertnstert.2018.06.005

    • PubMed
    • Google Scholar
46. 1. Palermo GD
    2. Takeuchi T
    3. Rosenwaks Z

    (2002) Technical approaches to correction of oocyte aneuploidy

    Human Reproduction 17:2165–2173.

    https://doi.org/10.1093/humrep/17.8.2165

    • PubMed
    • Google Scholar
47. 1. Paull D
    2. Emmanuele V
    3. Weiss KA
    4. Treff N
    5. Stewart L
    6. Hua H
    7. Zimmer M
    8. Kahler DJ
    9. Goland RS
    10. Noggle SA
    11. Prosser R
    12. Hirano M
    13. Sauer MV
    14. Egli D

    (2013) Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants

    Nature 493:632–637.

    https://doi.org/10.1038/nature11800

    • PubMed
    • Google Scholar
48. 1. Pellicer A
    2. Oliveira N
    3. Ruiz A
    4. Remohí J
    5. Simón C

    (1995) Exploring the mechanism(s) of endometriosis-related infertility: an analysis of embryo development and implantation in assisted reproduction

    Human Reproduction 10 Suppl 2:91–97.

    https://doi.org/10.1093/humrep/10.suppl_2.91

    • PubMed
    • Google Scholar
49. 1. Reader K
    2. Stanton J-A
    3. Juengel J

    (2017) The role of oocyte organelles in determining developmental competence

    Biology 6:35.

    https://doi.org/10.3390/biology6030035

    • Google Scholar
50. 1. Sathananthan AH

    (1997)

    Ultrastructure of the human egg

    Human Cell 10:21–38.

    • PubMed
    • Google Scholar
51. 1. Sauer MV
    2. Paulson RJ
    3. Lobo RA

    (1990) A preliminary report on oocyte donation extending reproductive potential to women over 40

    New England Journal of Medicine 323:1157–1160.

    https://doi.org/10.1056/NEJM199010253231702

    • PubMed
    • Google Scholar
52. 1. Sharpley MS
    2. Marciniak C
    3. Eckel-Mahan K
    4. McManus M
    5. Crimi M
    6. Waymire K
    7. Lin CS
    8. Masubuchi S
    9. Friend N
    10. Koike M
    11. Chalkia D
    12. MacGregor G
    13. Sassone-Corsi P
    14. Wallace DC

    (2012) Heteroplasmy of mouse mtDNA is genetically unstable and results in altered behavior and cognition

    Cell 151:333–343.

    https://doi.org/10.1016/j.cell.2012.09.004

    • PubMed
    • Google Scholar
53. 1. St John JC
    2. Makanji Y
    3. Johnson JL
    4. Tsai TS
    5. Lagondar S
    6. Rodda F
    7. Sun X
    8. Pangestu M
    9. Chen P
    10. Temple-Smith P

    (2019) The transgenerational effects of oocyte mitochondrial supplementation

    Scientific Reports 9:6694.

    https://doi.org/10.1038/s41598-019-43135-4

    • PubMed
    • Google Scholar
54. 1. Tachibana M
    2. Sparman M
    3. Sritanaudomchai H
    4. Ma H
    5. Clepper L
    6. Woodward J
    7. Li Y
    8. Ramsey C
    9. Kolotushkina O
    10. Mitalipov S

    (2009) Mitochondrial gene replacement in primate offspring and embryonic stem cells

    Nature 461:367–372.

    https://doi.org/10.1038/nature08368

    • PubMed
    • Google Scholar
55. 1. Trounson A
    2. Leeton J
    3. Besanko M
    4. Wood C
    5. Conti A

    (1983) Pregnancy established in an infertile patient after transfer of a donated embryo fertilised in vitro

    BMJ 286:835–838.

    https://doi.org/10.1136/bmj.286.6368.835

    • PubMed
    • Google Scholar
56. 1. Van Blerkom J
    2. Davis PW
    3. Lee J

    (1995) ATP content of human oocytes and developmental potential and outcome after in-vitro fertilization and embryo transfer

    Human Reproduction 10:415–424.

    https://doi.org/10.1093/oxfordjournals.humrep.a135954

    • PubMed
    • Google Scholar
57. 1. Van Blerkom J

    (2011) Mitochondrial function in the human oocyte and embryo and their role in developmental competence

    Mitochondrion 11:797–813.

    https://doi.org/10.1016/j.mito.2010.09.012

    • PubMed
    • Google Scholar
58. 1. Wells D

    (2017) Mitochondrial DNA quantity as a biomarker for blastocyst implantation potential

    Fertility and Sterility 108:742–747.

    https://doi.org/10.1016/j.fertnstert.2017.10.007

    • PubMed
    • Google Scholar
59. 1. White YA
    2. Woods DC
    3. Takai Y
    4. Ishihara O
    5. Seki H
    6. Tilly JL

    (2012) Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women

    Nature Medicine 18:413–421.

    https://doi.org/10.1038/nm.2669

    • PubMed
    • Google Scholar
60. Report

    1. WHO

    (2017)

    Global Prevalence of Infertility, Infecundity and Childlessness

    World Health Organization.

    • Google Scholar
61. 1. Yamada M
    2. Egli D

    (2017) Genome transfer prevents fragmentation and restores developmental potential of developmentally compromised postovulatory aged mouse Oocytes

    Stem Cell Reports 8:576–588.

    https://doi.org/10.1016/j.stemcr.2017.01.020

    • PubMed
    • Google Scholar
62. 1. Yi YC
    2. Chen MJ
    3. Ho JY
    4. Guu HF
    5. Ho ES

    (2007) Mitochondria transfer can enhance the murine embryo development

    Journal of Assisted Reproduction and Genetics 24:445–449.

    https://doi.org/10.1007/s10815-007-9161-6

    • PubMed
    • Google Scholar
63. 1. Zhang J
    2. Liu H
    3. Luo S
    4. Lu Z
    5. Chávez-Badiola A
    6. Liu Z
    7. Yang M
    8. Merhi Z
    9. Silber SJ
    10. Munné S
    11. Konstantinidis M
    12. Wells D
    13. Tang JJ
    14. Huang T

    (2017) Live birth derived from oocyte spindle transfer to prevent mitochondrial disease

    Reproductive BioMedicine Online 34:361–368.

    https://doi.org/10.1016/j.rbmo.2017.01.013

    • PubMed
    • Google Scholar

Thank you for submitting your article "Maternal spindle transfer overcomes embryo developmental arrest caused by ooplasmic defects in mice" for consideration by eLife. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Didier Stainier as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, the authors present results of their study on the efficacy of cytoplasmic replacement in oocytes using mitochondrial spindle transfer (MST) for overcoming poor preimplantation development in the mouse model. MST can be performed after oocyte vitrification and frozen/thawed cytoplasts but not spindles show poor development after MST. Whole cytoplasmic replacement in mature oocytes from NZB/OlaHsd mice with donor cytoplasm derived from B6CBAF1 mice can rescue poor fertilization, cleavage and blastocyst formation typical for NZB mice.

Essential revisions:

1) Introduction and summary of the literature: "The introduction is very selective especially related to autologous mitochondrial supplementation and appears to have been crafted to sell the authors' point of view. There are data to suggest that mitochondrial supplementation works and the effect that is has on gene expression in embryos and on litter size. Furthermore, children have been produced using this approach. The authors are requested to ensure that there is scientific balance in the Introduction for each aspect discussed." Please revise.

2) "There is no detail about the depth of the sequencing. Ion Torrent is not a reliable sequencing platform – it produces too many unreliable reads – you need to use a more reliable platform such as MiSeq. The levels of heteroplasmy need to be assessed on a range of tissues to determine if you see uniform similarities in transmission. At the moment, these data are not convincing as too few tissues are assessed."

"Conclusions on mtDNA heteroplasmy are weak because results are based on detection of only one SNP difference between NZB/OlaHsd and B6CBAF1 strains. It is likely that mtDNA haplotypes of these two strains differ on more than 90 SNPs. Therefore, authors should monitor heteroplasmy on each of these positions. This should be done by whole mtDNA sequencing, which is required for conclusive heteroplasmy assays post MRT."

Please provide additional sequencing data to solidify this key point.

3) "All pups (F2) were born alive, respired normally and grew to adulthood without manifesting any physiological or behavioral alteration.” and “Gross necropsies of the parents and offspring were also performed during the 5 generations, with no pathological findings observed.” Where are these data and how much depth was there to these analyses? This is critical given that a recent paper has shown that autologous mitochondrial supplementation can lead to a heart defect. Clarify to what depth mice were studied at autopsy.

4) "Authors used NZB strain as an example of a poor breeder strain. Strikingly, F1 females derived from MST that are still genetically NZO produced large litters (~8 pups) according to Supplementary file 1. It seems that authors show only one litter, which seems to be large even in unmanipulated NZO strain. It would be useful to show if F1 females maintain high productivity over time compared to NZO females (which should be also included in the table). If MST transfer improved NZO female's fecundity this could indicate that their breeding problems are mitochondria related and replacing mitochondria could improve the performance of this strain. Which would be of interest also from the clinical perspective. This technique could potentially reveal mitochondrial causes of infertility in patients which can be hereditary in the female lineage Women treated for ooplasm deficiency could pass this to their daughters." Please comment on the reviewer's observation.

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Thank you for resubmitting your work entitled "Maternal spindle transfer overcomes embryo developmental arrest caused by ooplasmic defects in mice" for further consideration at eLife. Your revised article has been favorably evaluated by Didier Stainier (Senior Editor), a Reviewing Editor, and three reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

Reviewers remain concerned about the strength of the evidence to show that the animals were indeed normal. Were any organs preserved for histological examination? If so, it would be reasonable to examine at least a subset of these. The reviewers feel that given the impetus to take this technology to the clinic, this information from your rather extensive preclinical study is of considerable importance. Any additional data related to this point would be most valuable.

Reviewer #1:

Whilst I am not convinced by the explanation for the use of Ion Torrent, it is not my primary concern.

I am primarily concerned about the lack of detail related to the health and well-being of the offspring. The subsection “Developmental potential of MST mice and mtDNA heteroplasmy fate” does not provide sufficient information to determine if the animals were healthy or not and no data are presented. There is also no detail in the Materials and methods section. Macroscopic and microscopic investigations need to be performed. Currently, there is a drive to push this form of assisted reproductive technology into clinical practice in various countries and the real question relates to the health and well-being of the offspring. A number of studies have offered accounts of the fate of mtDNA that is carried over. Your study requires some novelty and macroscopic and microscopic investigations would provide this.

I am not prepared to support the publication of a manuscript related to this form of assisted reproductive technology that does not deal with the crucial question about the health and well-being of the offspring. Three lines of text is simply not sufficient.

Reviewer #2:

Authors provided additional information requested by reviewers such as references, added text and supplementary data. Other comments were addressed in the rebuttal by providing references supporting their argument but without adding additional data (although cited papers did not always agree – see point 1).

I am satisfied with most of the issues addressed but would like to hear from other reviewers if their comments were sufficiently addressed.

1) Addressing comment 2 that 5 tissues are insufficient to determine transmission of heteroplasmy authors cited two papers (Sharpley et al., 2012; Jenuth et al., 1997) saying that they have tested "a similar number" of tissues when in fact they used twice as many (10 or 9).

Reviewer #3:

I believe that the revision did not address the main concern expressed by the reviewers that whole mtDNA sequencing (MiSeq) is required to validate conclusions on heteroplasmy. It is standard now to validate sequencing by two independent approaches. The author's arguments in the rebuttal are not convincing.

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Thank you for resubmitting your work entitled "Maternal spindle transfer overcomes embryo developmental arrest caused by ooplasmic defects in mice" for further consideration by eLife. Your revised article has been evaluated by Didier Stainier (Senior Editor) and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance.

You will see that one reviewer continues to have concern over the scope of your assessment. Although these concerns stem from genuine concern over the interpretation of the study, we think that you have gone some way to address this with additional data. Therefore, some comment in the Discussion to indicate that additional work would be required to fully assess safety issues.

Reviewer #1:

I am pleased to see that the authors have taken on extra work to seek to validate their claims regarding the safety of MST.

I note that the authors have undertaken the histopathology analysis. However, I am surprised to see that they have restricted themselves to four organs. Likewise, as argued by one of the other reviewers, they do not carry out mtDNA analysis on all tissues. Therefore, the arguments they present are only partially valid. The reason for this is that mtDNA, and specifically mtDNA mutations (as in disease) or variants (in non-pathological situations), do not segregate neutrally, or evenly, amongst all the tissues / organs but rather in a random manner. Therefore, without having analysis of all tissues and organs (or at least 10 as agreed by another reviewer), the outcomes are only indicative of what has been analysed. I, further, note that muscle has not been analysed and myopathies are associated with mtDNA disease and, in the disease state, muscle often carries high loads of mutant mtDNA, which affects OXPHOS function (mtDNA encodes for key genes of the electron transfer chain that performs OXPHOS).

In conclusion, I think this is an important study but it is being held back though either reluctance or a lack of understanding of mtDNA genetics and, specifically, transmission and segregation of the mitochondrial genome. Either way, this results in the conclusions being inconclusive.

Essential revisions:

1) Introduction and summary of the literature: "The introduction is very selective especially related to autologous mitochondrial supplementation and appears to have been crafted to sell the authors' point of view. There are data to suggest that mitochondrial supplementation works and the effect that is has on gene expression in embryos and on litter size. Furthermore, children have been produced using this approach. The authors are requested to ensure that there is scientific balance in the Introduction for each aspect discussed." Please revise.

We agree that the original Introduction as submitted was overly brief in describing previous studies on mitochondrial supplementation. This was due to the need to fully convey essential details to introduce our hypothesis, while keeping the text as succinct as possible. As stated by the reviewers, there are multiple studies in animal models that have described benefits of the technique to treat infertility (Yi et al., 2007; El Shourbagy et al., 2006; Hua et al., 2014) and, importantly, children resultant from the application of this technique have been born (Fakih et al., 2015). We have rewritten this section of our Introduction to better introduce autologous mitochondrial supplementation.

The following references have also been added to the current version of the manuscript:

Johnson, J., Canning, J., Kaneko, T., Pru, J.K., and Tilly, J.L. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004; 428: 145–150.

White, Y.A., Woods, D.C., Takai, Y., Ishihara, O., Seki, H., and Tilly, J.L. Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women. Nat Med. 2012; 18: 413–421.

Yi, Y.C., Chen, M.J., Ho, J.Y., Guu, H.F., and Ho, E.S.Mitochondria transfer can enhance the murine embryo development.J Assist Reprod Genet.2007;24:445–449.

El Shourbagy, S.H., Spikings, E.C., Freitas, M., and St. John, J.C.Mitochondria directly influence fertilisation outcome in the pig.Reproduction.2006;131:233–245.

Hua, S., Zhang, Y., Li, X.C., Ma, L.B., Cao, J.W., Dai, J.P. et al.Effects of granulosa cell mitochondria transfer on the early development of bovine embryos in vitro.Cloning Stem Cells.2007;9:237–246.

Fakih, M.H.S.M., Szeptycki, J., dela Cruz, D.B., Lux, C., Verjee, S., Burgess, C.M., Cohn, G.M., and Casper, R.F. The AUGMENT treatment: physician reported outcomes of the initial global patient experience. JFIV Reprod Med Genet. 2015; 3: 154.

St John JC, Makanji Y, Johnson JL, Tsai TS, Lagondar S, Rodda F, Sun X, Pangestu M, Chen P, Temple-Smith P. The transgenerational effects of oocyte mitochondrial supplementation. Sci Rep. 2019 Apr 30;9(1):6694.

2) "There is no detail about the depth of the sequencing. Ion Torrent is not a reliable sequencing platform – it produces too many unreliable reads – you need to use a more reliable platform such as MiSeq. The levels of heteroplasmy need to be assessed on a range of tissues to determine if you see uniform similarities in transmission. At the moment, these data are not convincing as too few tissues are assessed."

"Conclusions on mtDNA heteroplasmy are weak because results are based on detection of only one SNP difference between NZB/OlaHsd and B6CBAF1 strains. It is likely that mtDNA haplotypes of these two strains differ on more than 90 SNPs. Therefore, authors should monitor heteroplasmy on each of these positions. This should be done by whole mtDNA sequencing, which is required for conclusive heteroplasmy assays post MRT. "

Please provide additional sequencing data to solidify this key point.

We agree that depth of sequencing should be included in the manuscript to show reliability of data. In fact, care was taken to ensure that each sample was sequenced at great depth (mean: ~60,000 reads) to ensure high accuracy and sensitivity of variant calling. We now included mean sequencing coverages (± SDs and ranges) of alleles at the variant site in footnotes of Supplementary file 1, Supplementary file 2 and Supplementary file 4. In addition, we prepared an excel file for reviewers with source data for these analyses (see Source data files), listing exact sequencing coverages at the variant site in all processed samples. These files, together with footnotes included in relevant tables, show that sequencing depth was consistently high and sufficient for variant calling throughout all samples tested.

We agree that it is essential to obtain accurate sequencing reads when determining variant ratios. We believe that the Ion Torrent is a highly reliable sequencing platform and well‑suited for variant analysis. It is routinely used for this purpose in research as well as clinical diagnostics and forensics (see referencesYang et al., 2018; Singh et al., 2013; Heeke et al., 2018; Churchill et al., 2018; below for recent examples). Furthermore, comparison of the Ion Torrent to other sequencers, including MiSeq, has not shown differences in performance (see referenceQuail et al., 2012). In our laboratory we use both platforms, the MiSeq and the Ion Torrent. For the present project we decided to use the Ion Torrent because it allows deep sequencing at much lower cost and much higher sample throughput than the MiSeq. Importantly, the Ion Torrent is coupled with a powerful server for direct processing of generated sequencing data, utilising software specifically developed for Ion Torrent raw data analysis. The verified Torrent Variant Caller plug‑in was used to determine variant ratios. Optimised, pre-set parameters were applied for variant calling. Some parameters were further customised to increase variant calling accuracy: (1)Settings for “Somatic” variants analysed at “High Stringency” were applied to enable low frequency variant detection at a minimal false‑positive call rate. (2)The read depth was down sampled to 20,000, rather than 2,000 reads as recommended, to increase accuracy of variant calls. (3)A “HotSpot Region” BED file, defining the exact genomic coordinate of the assessed nucleotide, in addition to a “Target Region” BED file, was applied to increase variant calling sensitivity at the assessed locus. Additionally, sequencing results of all samples were visualized in the integrative genomics viewer (IGV) to confirm variant calls and to ensure variant calls/low-level heteroplasmies were not ignored. Overall, we believe that our data is very accurate. Of note, in addition to the known variant site we also assessed all other nucleotides in sequences flanking the variant site. No sequencing artefacts/errors were detected in any position in the ~100bp amplicons in any of the samples.

We have edited the Materials and methods section to further clarify this point.

We agree that it is important to assess heteroplasmy levels in a range of adult mice tissues to determine mtDNA transmission and possible unequal distribution. For these reasons, we tested a total of 110organs and tissues of different energy needs (22tails, 22hearts,22livers, 22brains and 22kidneys). These were derived from 22animals (10female and 12male mice) from five consecutive generations (6xF1, 4xF2, 4xF3, 4xF4 and 4xF5, please see Supplementary file 4). Detected heteroplasmy levels were always comparable between organ/tissue types of individual mice and between mice of same generation. Moreover, heteroplasmy levels in organs/tissues of F1mice were comparable to the heteroplasmy levels detected in embryo biopsies. This data suggests that the types of organs/tissues and numbers of mice/generations analysed were sufficient to assess mtDNA transmission. Of note, published studies of similar type assessed similar numbers and organs/tissues (see referencesJenuth et al., 1997; Sharpley et al., 2012) to what we present here.

Accurate mtDNA heteroplasmy levels can be obtained from the analysis of a single SNP, since all polymorphic sites are inherited together. In fact, the analysis of a single polymorphic nucleotide is routinely used for the quantification of heteroplasmy levels and mtDNA carry-over rates (see referencesJenuth et al., 1997; Sharpley et al., 2012; Tachibana et al., 2009; Hyslop et al., 2016). The SNP at position m.3932 was used for mtDNA quantification in the present study. Differing B6CBAF1 and NZB alleles were initially confirmed by minisequencing. High accuracy and high sensitivity in heteroplasmy detection using the specified polymorphic nucleotide was confirmed using artificial mixtures of genomic DNA (see Supplementary file 1). Of note, the analysis of single nucleotides for mtDNA heteroplasmy quantification is a well‑established procedure in our laboratory and has been extensively validated on a range of samples (including human) for several other research projects as well clinical diagnostics. Therefore, we believe that the conclusions drawn in the present study are legitimate.

3) "All pups (F2) were born alive, respired normally and grew to adulthood without manifesting any physiological or behavioral alteration.” and “Gross necropsies of the parents and offspring were also performed during the 5 generations, with no pathological findings observed. Where are these data and how much depth was there to these analyses? This is critical given that a recent paper has shown that autologous mitochondrial supplementation can lead to a heart defect." Clarify to what depth mice were studied at autopsy.

The health, reproductive performance and welfare were monitored in all mice born from F1 until F5 resultant from the MST-derived lineage (in total, 239 mice). All mice analysed grew healthy and those selected for mating presented good fertility condition. Additionally, at weaning (21 days after birth), all pups showed normal appearance and appropriate size with no differences detected among gender, nor were any episodes of premature death reported. A gross necropsy of all parental mice (F1-F5) was performed, meaning that organs were observed macroscopically with no pathological findings observed, in terms of size, texture or morphological appearance, as detailed in subsection “Developmental potential of MST mice and mtDNA heteroplasmy fate” of the revised manuscript. In addition, some organs (tail, heart, brain, kidneys and liver) were harvested for analysis of mtDNA heteroplasmy, as stated in the manuscript.

4) "Authors used NZB strain as an example of a poor breeder strain. Strikingly, F1 females derived from MST that are still genetically NZO produced large litters (~8 pups) according to Supplementary file 1. It seems that authors show only one litter, which seems to be large even in unmanipulated NZO strain. It would be useful to show if F1 females maintain high productivity over time compared to NZO females (which should be also included in the table). If MST transfer improved NZO female's fecundity this could indicate that their breeding problems are mitochondria related and replacing mitochondria could improve the performance of this strain. Which would be of interest also from the clinical perspective. This technique could potentially reveal mitochondrial causes of infertility in patients which can be hereditary in the female lineage Women treated for ooplasm deficiency could pass this to their daughters." Please comment on the reviewer's observation.

We thank the reviewer for this interesting observation. Our data indicate that over the five generations the MST-derived mice were crossed and followed, the litter size was large and stable (average of 7.4 pups, see Supplementary file 3). Based on the literature and information provided by the commercial provider (Invigo), poor reproductive performance is expected for NZB/OlaHsd mice, with litter sizes of 3.8 at weaning and colony output 0.5 young/female/week (Festing, 1976; Fernandes et al., 1973; Hansen et al., 1973). Unfortunately, we did not follow the NZB controls after F1, as the main aim of our study was to evaluate the health, welfare and reproductive performance of the mice resultant from MST. We could hypothesize based on this observation that the MST technique can potentially reveal mitochondrial or cytoplasmic causes of infertility, but we do not have a direct control group to support this finding. Our group is currently investigating this question as part of another study that is being carried out.

We have added this to the Discussion of the revised manuscript.

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Reviewers remain concerned about the strength of the evidence to show that the animals were indeed normal. Were any organs preserved for histological examination? If so, it would be reasonable to examine at least a subset of these. The reviewers feel that given the impetus to take this technology to the clinic, this information from your rather extensive preclinical study is of considerable importance. Any additional data related to this point would be most valuable.

Reviewer #1:

Whilst I am not convinced by the explanation for the use of Ion Torrent, it is not my primary concern.

I am primarily concerned about the lack of detail related to the health and well-being of the offspring. The subsection “Developmental potential of MST mice and mtDNA heteroplasmy fate” does not provide sufficient information to determine if the animals were healthy or not and no data are presented. There is also no detail in the Materials and methods section. Macroscopic and microscopic investigations need to be performed. Currently, there is a drive to push this form of assisted reproductive technology into clinical practice in various countries and the real question relates to the health and well-being of the offspring. A number of studies have offered accounts of the fate of mtDNA that is carried over. Your study requires some novelty and macroscopic and microscopic investigations would provide this.

I am not prepared to support the publication of a manuscript related to this form of assisted reproductive technology that does not deal with the crucial question about the health and well-being of the offspring. Three lines of text is simply not sufficient.

Following this reviewer’s suggestions we have performed additional MST experiments both using both NZB and B6 strain oocytes. Blastocysts were transferred and 12 adult animals were examined in detail through histopathological analyses. For this set of experiments, necropsies and histological examination of the 12 animals (4 from resultant from ICSI in B6 strain, 3 from reciprocal MST in B6 and 5 NZB-sp/B6-cyt MST assays) was done blindly by the pathologist (see attached report where G1 = ICSI-B6, G2 = B6-sp/B6-cyt MST, G3 = NZB-sp/B6-cyt MST). We have also included representative findings in a new figure: Figure 4—figure supplement 1).

We have updated accordingly the Results section:

“Gross necropsies of the parents and offspring were performed during the 5 generations, with no pathological findings observed. In the 239 mice analysed, all organs showed a normal size, texture and morphological appearance. Additionally, histopathological examinations were performed in organs including heart, kidney, liver and brain, in the F1 mice generated for this purpose by MST B6-sp/B6-cyt (n=3), MST NZB-sp/B6-cyt (n=5) and control B6 (n=4) groups. Except for a pericardium focal inflammation in one animal of the B6 control group, neither of the animals showed any lesions or visible abnormalities (Figure 4—figure supplement 1). Taken together, these results support the notion that MST can efficiently produce healthy, fertile and viable offspring.”

And the Materials and methods section (Histological analysis):

“For histological evaluation, tissue samples from heart, liver, kidney and brain of 4 ICSI-B6 control, 3 B6-sp/B6-cyt MST and 5 NZB-sp/B6-cyt MST mice were collected at 6 weeks of age. Mice were first perfused with PBS and then with 5% formaldehyde solution. Subsequently, tissues were fixed overnight at 4°C in 5% formaldehyde and embedded in paraffin wax, sliced in 4-μm sections and stained with hematoxylin and eosin staining (H&E). The atrium, valves and myocardium of heart; both kidneys (through longitudinal and transverse sections), liver and gall bladder, forebrain, midbrain and hindbrain were evaluated. Histological analysis was carried out blindly using mouse identification codes for group assignment that were unknown to the evaluator.”

As stated by the pathologist in the report attached, macroscopic observations revealed that all animals were well nourished, well groomed and active; with no dermal lesions, nasal, ocular or genital discharges seen. Thoracic and abdominal viscera did not show abnormalities either. Additionally, histological analysis tissues performed in heart, kidney, liver and brain sections showed no apparent lesions in any of the organs evaluated in mice derived from NZB sp-/B6-cyt MST and B6-sp/B6-cyt MST embryos. Neither of the animals evaluated presented lesions of significance, except for one mouse derived from B6-ICSI control group that showed a pericardium inflammation.

In addition, we have also performed an extensive comparison between Ion PGM and Illumina MiSeq sequencing platforms using up to five different allele variants in tissues with known different heteroplasmy levels, please see detailed answer to reviewer #3 below.

Reviewer #2:

Authors provided additional information requested by reviewers such as references, added text and supplementary data. Other comments were addressed in the rebuttal by providing references supporting their argument but without adding additional data (although cited papers did not always agree – see point 1).

I am satisfied with most of the issues addressed but would like to hear from other reviewers if their comments were sufficiently addressed.

1) Addressing comment 2 that 5 tissues are insufficient to determine transmission of heteroplasmy authors cited two papers (Sharpley et al., 2012; Jenuth et al., 1997) saying that they have tested "a similar number" of tissues when in fact they used twice as many (10 or 9).

We are glad that the information provided in the previous revision mostly satisfied reviewer #2. We have included histological evidence that supports the notion that the mice generated by spindle transfer are normal and provided additional data that confirms the reliability of the Ion PGM platform used to determine heteroplasmy in the different organs of the mice of the different generations.

Reviewer #3:

I believe that the revision did not address the main concern expressed by the reviewers that whole mtDNA sequencing (MiSeq) is required to validate conclusions on heteroplasmy. It is standard now to validate sequencing by two independent approaches. The author's arguments in the rebuttal are not convincing.

As indicated in the previous revision of our manuscript, comparison of the Ion Torrent to other sequencers, including MiSeq, had not shown differences in performance (see reference Quail et al., 2012).

Nevertheless, we decided to address the reviewers concern by first doing a direct comparison of the performance and accuracy of the IonTorrent PGM machine and Illumina’s MiSeq; and secondly by not only assaying 1 SNP from one mtDNA amplicon, but for a total of 3 amplicons, analyzing a total of 5 mitochondrial SNPs (B6CBAF1/NZB: m.3932A/G, m.2798C/T; m.2814T/C; m.3194T/C; m.3260A/G):

We describe this in detail in the Materials and methods section:

“To ensure both the validity of assessment of a single SNP for mtDNA carryover analysis and the accuracy of the utilized sequencing platform (Ion PGM); a second set of experiments was performed, which included analysis of four additional SNPs (B6CBAF1>NZB: m.2798C>T; m.2814T>C; m.3194T>C; m.3260A>G) utilizing Illumina’s MiSeq System sequencing platform. […] Furthermore, gDNA samples from organs of three individual mice were sequenced and results compared to those obtained by PGM sequencing.”

We have also updated the Results section accordingly :

“To verify validity of mtDNA carryover assessment by analysis of a single SNP and to ensure reliability of the utilised sequencing platform, four additional SNPs (B6CBAF1/NZB: m.2798C/T; m.2814T/C; m.3194T/C; m.3260A/G) were analysed on a different sequencer (Illumina’s MiSeq). The presence of different alleles was also confirmed by minisequencing”

(see Materials and methods and Supplementary file 2 for further details; and Figure 3—figure supplement 2). And in the Results section:

“These quantifications based on a single SNP in an Ion PGM sequencer were corroborated by using an additional sequencing platform (Illumina’s MiSeq) and 5 SNPs, as described above. Artificially constructed samples, composed of gDNA from both mouse strains mixed in different ratios, and gDNA from 5 organs of selected adult mice from F1-3 generations were analysed (Figure 3—figure supplement 2, Figure 4—figure supplement 2, Supplementary files 2 and 6). These results suggest that low levels of mtDNA heteroplasmy resultant from MST typicallly result in a homoplasmic state in offspring within a few generations, without reversion (Supplementary files 5 and 6).”

These results are summarized in new Supplementary files 2 and 6 (with the corresponding source data in 2 data files). The direct comparison of measurements of 5 organ samples from MST mice from 3 generations between the 2 sequencing platforms is depicted in Figure 4—figure supplement 2.

Overall, our analyses show that there are no significant differences between the heteroplasmy levels regardless of whether we examine 1 mtDNA SNP or more; or the sequencing platform utilised. These new validations confirm that Ion PGM is reliable and well-suited for this type of variant analysis. Of note, the heteroplasmy levels of the offspring generated by MST is almost null from generation F3 (see Figure 4 and Figure 4—figure supplement 2 and Supplementary files 5 and 6), suggesting that the low mtDNA heteroplasmic levels result in homosplamic state in the offspring within a few generations and without reversion. Therefore, we believe that the conclusions drawn in the present study are legitimate.

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Reviewer #1:

I am pleased to see that the authors have taken on extra work to seek to validate their claims regarding the safety of MST.

I note that the authors have undertaken the histopathology analysis. However, I am surprised to see that they have restricted themselves to four organs. Likewise, as argued by one of the other reviewers, they do not carry out mtDNA analysis on all tissues. Therefore, the arguments they present are only partially valid. The reason for this is that mtDNA, and specifically mtDNA mutations (as in disease) or variants (in non-pathological situations), do not segregate neutrally, or evenly, amongst all the tissues/organs but rather in a random manner. Therefore, without having analysis of all tissues and organs (or at least 10 as agreed by another reviewer), the outcomes are only indicative of what has been analysed. I, further, note that muscle has not been analysed and myopathies are associated with mtDNA disease and, in the disease state, muscle often carries high loads of mutant mtDNA, which affects OXPHOS function (mtDNA encodes for key genes of the electron transfer chain that performs OXPHOS).

In conclusion, I think this is an important study but it is being held back though either reluctance or a lack of understanding of mtDNA genetics and, specifically, transmission and segregation of the mitochondrial genome. Either way, this results in the conclusions being inconclusive.

In the previous version of our revised manuscript we had included histopathological examinations that had been performed in vital organs, including heart, kidney, liver and brain. We have now extended these examinations to additional tissues from the same animals, as suggested. We included the analysis in both skeletal tibial and quadriceps muscle and urinary bladder for smooth muscle. Additionally, we have also processed organs from the reproductive tract and accessory glands in both males (testis, epididymis, seminal vesicles, prostate, coagulating glands, ampullary glands and bulbourethral glands) and females (ovaries, oviducts, uterine horns). Taken together we have examined over 10 organs/tissues from each animal. None of the animals showed any lesions or visible abnormalities. Representative images from additional stainings are now included in Figure 4—figure supplements 1 and 2.

On the other hand, we have tried to tone down the claims that the MST animals were “healthy” and emphasized in the revised Discussion that the conclusions regarding the animals health and heteroplasmy levels are drawn only from the organs we assessed.

References:

Churchill, J. D., Stoljarova, M., King, J. L. & Budowle, B. Massively parallel sequencing-enabled mixture analysis of mitochondrial DNA samples. Int. J. Legal Med. 132, 1263–1272 (2018).

Festing MF. Phenotypic variability of inbred and outbred mice. Nature. 1976 Sep 16;263(5574):230-2.

Heeke, S. et al. Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients. Cancers (Basel). 10, 88 (2018).

Hyslop, L. A. et al. Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. Nature 534, 383–386 (2016).

Jenuth, J. P., Peterson, A. C. & Shoubridge, E. A. Tissue-specific selection for different mtDNA genotypes in heteroplasmic mice. Nat. Genet. 16, 93–95 (1997).

Quail, M. et al. A tale of three next generation sequencing platforms: comparison of Ion torrent, pacific biosciences and illumina MiSeq sequencers. BMC Genomics 13, 341 (2012).

Sharpley, M. S. et al. Heteroplasmy of mouse mtDNA is genetically unstable and results in altered behavior and cognition. Cell 151, 333–343 (2012).

Singh, R. R. et al. Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes. J. Mol. Diagnostics 15, 607–622 (2013).

Tachibana, M. et al. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 461, 367–372 (2009).

Yang, D. et al. An SNP panel for the analysis of paternally inherited alleles in maternal plasma using ion Torrent PGM. Int. J. Legal Med. 132, 343–352 (2018).

Author details

1. Nuno Costa-Borges

   Embryotools, Parc Cientific de Barcelona, Barcelona, Spain

   Contribution

   Conceptualization, Data curation, Supervision, Validation, Investigation, Methodology, Project administration

   For correspondence

   nuno.borges@embryotools.com

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-2073-7515

2. Katharina Spath

   1. Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom
   2. Juno Genetics, Winchester House, Oxford Science Park, Oxford, United Kingdom

   Contribution

   Conceptualization, Data curation, Investigation, Methodology

   Competing interests

   No competing interests declared

3. Irene Miguel-Escalada

   Genomics and Bioinformatics, Centre for Genomic Regulation, Barcelona, Spain

   Contribution

   Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Methodology

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-3461-6404

4. Enric Mestres

   Embryotools, Parc Cientific de Barcelona, Barcelona, Spain

   Contribution

   Data curation, Investigation, Methodology

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-6140-6416

5. Rosa Balmaseda

   PCB Animal Facility, Parc Cientific de Barcelona, Barcelona, Spain

   Contribution

   Investigation, Methodology

   Competing interests

   No competing interests declared

6. Anna Serafín

   PCB Animal Facility, Parc Cientific de Barcelona, Barcelona, Spain

   Contribution

   Investigation

   Competing interests

   No competing interests declared

7. Maria Garcia-Jiménez

   Embryotools, Parc Cientific de Barcelona, Barcelona, Spain

   Contribution

   Data curation, Investigation, Methodology

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-3321-8869

8. Ivette Vanrell

   Embryotools, Parc Cientific de Barcelona, Barcelona, Spain

   Contribution

   Investigation, Methodology

   Competing interests

   No competing interests declared

9. Jesús González

   PCB Animal Facility, Parc Cientific de Barcelona, Barcelona, Spain

   Contribution

   Investigation, Methodology

   Competing interests

   No competing interests declared

10. Klaus Rink

    Embryotools, Parc Cientific de Barcelona, Barcelona, Spain

    Contribution

    Resources, Validation, Methodology

    Competing interests

    No competing interests declared

11. Dagan Wells

    1. Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom
    2. Juno Genetics, Winchester House, Oxford Science Park, Oxford, United Kingdom

    Contribution

    Conceptualization, Supervision, Funding acquisition, Methodology, Project administration

    Competing interests

    No competing interests declared

12. Gloria Calderón

    Embryotools, Parc Cientific de Barcelona, Barcelona, Spain

    Contribution

    Conceptualization, Resources, Supervision, Funding acquisition, Project administration

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0003-3235-0323

• 4,834

  Page views

• 383

  Downloads

• 18

  Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.